Clinical Trial Update: A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating daratumumab in combination with pomalidomide, dexamethasone, and all-trans retinoic acid in multiple myeloma was terminated; results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)
• Pomalyst (pomalidomide)
• Vesanoid (all-trans retinoic acid)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2025-02-25